Liraglutide reduces the apoptosis of feeding and appetite-suppressing neurons in the hypothalamus of obese rats association with the PI3K/AKT/Foxo1 pathway.
Exp Brain Res · 2026
Last updated 2026-05-28In a study of 40 rats fed a high-fat diet for 12 weeks, those given liraglutide (200 µg/kg/day) for 6 weeks showed less damage and fewer dying neurons in the brain region that controls appetite compared to rats given only saline. Liraglutide also lowered blood sugar and insulin resistance, increased activity in appetite-suppressing neurons, and decreased activity in appetite-stimulating neurons (p < 0.05).
AI summary of the abstract below.
| Journal | Exp Brain Res, 2026 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
| Conditions studied | Obesity |
Abstract
OBJECTIVE: Obesity-induced inflammation in the hypothalamus disrupts the function of neurons that regulate appetite, particularly proopiomelanocortin (POMC) and neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons in the arcuate nucleus (ARC). Although Liraglutide, a GLP-1 analogue, exhibits neuroprotective properties, the underlying molecular mechanisms are unclear. In this study, we investigated whether Liraglutide protects hypothalamic neurons via the PI3K/AKT/Foxo1 pathway.
METHODS: Male SD rats (n = 40) were fed a high-fat (HFD) or normal-fat (NFD) diet for 12 weeks. The obese rats on the HFD received Liraglutide (200 µg/kg/day, HL) or saline (HS), while the NFD controls received Liraglutide (NL) or saline (NS) for 6 weeks. Metabolic parameters, neuronal ultrastructure (TEM/Nissl staining), apoptosis (TUNEL assay) and biomarkers of the PI3K/AKT/Foxo1 pathway were analysed using immunofluorescence, RT-PCR and Western blotting.
RESULTS: The HFD group showed more weight gain, higher fasting blood glucose levels, and insulin resistance compared to the NFD. Rats on the HFD showed neuronal damage (reduced Nissl bodies and nuclear fragmentation) and apoptosis (more TUNEL-positive cells) in the ARC. Liraglutide reversed these effects. The HL group showed lower levels of apoptosis compared to the HS group. At the same time, there was an increase in the activity of the POMC and a decrease in the NPY/AgRP (p < 0.05). Mechanistically, Liraglutide activates the PI3K/AKT pathway, reduces Foxo1 expression and balances Bcl-2/Bax apoptotic regulators.
CONCLUSION: Liraglutide improves hypothalamic neuronal apoptosis in obesity by activating the PI3K/AKT signalling pathway, which reduces Foxo1-mediated apoptosis and brings the balance of POMC and NPY neurons back to normal. These findings explain a key mechanism of Liraglutide's anti-obesity effects and demonstrate its potential for neuroprotection.
Verbatim abstract via PubMed 41865318 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.